Thionopyrrole Compounds

Abstract

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising the compounds, and methods of making and using the compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of autoimmune diseases and / or inflammatory conditions, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 176,109, filed April 16, 2021, U.S. Provisional Patent Application No. 63 / 216,418, filed June 29, 2021, and U.S. Provisional Patent Application No. 63 / 305,610, filed February 1, 2022, each of which is incorporated herein in its entirety for all purposes. The present disclosure generally relates to thienopyrrole compounds, pharmaceutical compositions comprising the compounds, and methods of making and using the compounds and pharmaceutical compositions. In some embodiments, the novel thienopyrrole compounds provided herein can be used to treat certain diseases and disorders, including, but not limited to, inflammatory conditions, systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis. [Background technology]

[0002] Toll-like receptors (TLRs) are a family of transmembrane immune receptors that sense pathogens, trigger innate immune responses, and stimulate adaptive immunity. TLR7 / 8 / 9 are endosome-localized TLRs that respond to single-stranded RNA (TLR7 / 8) or unmethylated DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Activation of TLR7 / 8 / 9 leads to inflammatory responses, including the production of type I interferons and proinflammatory cytokines, B cell activation and antibody production, and neutrophil NETosis. Abnormal activation of TLR7 / 8 / 9 contributes to elevated type I interferon responses, increased proinflammatory cytokines, and sustained autoantibody production, which can stimulate the chronic progression of various autoimmune diseases and inflammatory conditions, resulting in widespread inflammation and tissue damage. (Kawai et al., 2010, Nat Immunol 11, 373; Joosten et al., 2016, Nat Rev Rheomatol 12, 344; Crow et al., 2019, Lupus Sci Med 6, e000336; Garcia-Romo et al., 2011, Sci Transl Med 3, 73ra20; Kono et al., 2009, PNAS 106, 12061; Koh et al., 2013, J Immunol 190, 4982). Thus, there is a need for compounds that are potent TLR7 and / or TLR8 and / or TLR9 antagonists that are stable and exhibit effective pharmacokinetic and / or pharmacodynamic profiles. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Kawai et al.,2010,Nat Immunol 11,373, [Non-patent document 2] Joosten et al.,2016,Nat Rev Rheomatol 12,344 [Non-patent document 3] Crow et al.,2019,Lupus Sci Med 6,e000336 [Non-patent document 4] Garcia-Romo et al.,2011,Sci Transl Med 3,73ra20 [Non-Patent Document 5] Kono et al.,2009,PNAS 106,12061 [Non-patent document 6] Koh et al.,2013,J Immunol 190,4982 Summary of the Invention [Means for solving the problem]

[0004] In one embodiment, a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heterocyclyl and the 8- to 10-membered fused bicyclic heteroaryl each independently contain 1 to 4 R a optionally substituted with a group; R 2 But H, C 1~6 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6 the alkoxy is optionally substituted with 1 to 3 halogen groups; R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; C 1~4 the alkoxy is optionally substituted with 1 to 3 halogen groups; Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is C 1~6 Alkyl, C 2~6 Alkenyl, -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl and C 2~6 alkenyl, each independently, is selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from the group consisting of 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 But C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, R 13 But C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, R 7 But H, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, R 9 But C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R 11 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 11a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 12 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds, or pharmaceutically acceptable salts thereof, wherein each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0005] In one embodiment, provided herein is a pharmaceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0006] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0007] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptor 7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0008] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0009] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0010] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0011] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0012] In one embodiment, provided herein is a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0013] In one embodiment, provided herein is a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0014] In one embodiment, provided herein is a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0015] In one embodiment, provided herein is a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0016] In one embodiment, provided herein is a compound provided herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in therapy.

[0017] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0018] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptor 7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0019] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0020] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0021] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0022] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0023] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0024] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0025] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0026] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method for treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition. DETAILED DESCRIPTION OF THE INVENTION

[0027] I. Definition The following description is made with the understanding that the present disclosure should be considered as an example of claimed subject matter and is not intended to limit the scope of the appended claims to the particular embodiments illustrated. Headings used throughout this disclosure are for convenience only and should not be construed as limiting the scope of the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. It should be noted that, as used in this specification and the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "compound" includes a plurality of such compounds, and a reference to an "assay" includes a reference to one or more assays and equivalents thereof known to those skilled in the art, etc.

[0029] As used in this disclosure, the following words, phrases, and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0030] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment for a substituent. For example, -CONH2 is attached through a carbon atom. Dashes at the front or end of a chemical group are for convenience, and chemical groups may be designated with or without one or more dashes without losing their ordinary meaning. A wavy line drawn across a line in a structure indicates the point of attachment of the group. No directionality is indicated or implied by the order in which chemical groups are written or named, unless chemically or structurally required. A solid line extending from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of a substituent to that ring may be at any ring atom. For example, R in the following structure: aa may be attached to any of the five carbon ring atoms, or the hydrogen attached to the nitrogen ring atom may be attached to R aa may be replaced by: [ka] As another example, R in the following structure: aa So, [ka] and R aa can be attached at any of the numbered positions shown below: [ka]

[0031] A solid line projecting from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of the ring system to the remainder of the compound can be at any ring atom of the fused, bridged, or spirocyclic ring system. For example, in the structure: [ka] and The monocyclic heterocyclyl can be attached to the remainder of the compound at any of the numbered positions shown below: [ka] As another example, in the following fused bicyclic heterocyclic structure: [ka] and The fused bicyclic heterocyclyl can be attached to the rest of the compound at any of the eight numbered positions shown below: [ka]

[0032] "C u~v " prefix indicates that the following group has u to v carbon atoms. For example, "C 1~6 "Alkyl group" indicates that the alkyl group has 1 to 6 carbon atoms. Similarly, the term "x- to y-membered" ring, where x and y are numerical ranges (e.g., "3- to 12-membered heterocyclyl"), refers to a ring having x to y (i.e., 3 to 12) atoms, up to 80% of which may be heteroatoms such as N, O, S, P, etc., and the remaining atoms are carbon.

[0033] Also, certain commonly used alternative chemical names may or may not be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, etc. may also be referred to as "alkylene" or "alkylenyl" groups, or alkylyl groups, "arylene" or "arylenyl" groups, or aryl groups, respectively.

[0034] "Compounds disclosed herein" or "compounds of the disclosure" or "compounds provided herein" or "compounds described herein" refer to compounds of Formula I. Also included are the specific compounds of Examples 1-68.

[0035] Reference herein to "about" a value or parameter includes (and describes) embodiments related to the value or parameter itself. In certain embodiments, the term "about" includes the stated amount ±10%. In other embodiments, the term "about" includes the stated amount ±5%. In certain other embodiments, the term "about" includes the stated amount ±1%. Additionally, the term "about X" includes the description of "X."

[0036] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C 1~20 alkyl), having 1 to 12 carbon atoms (i.e., C 1~12 alkyl), having 1 to 8 carbon atoms (i.e., C 1~8 alkyl), having 1 to 6 carbon atoms (i.e., C 1~6 alkyl), having 1 to 4 carbon atoms (i.e., C 1~4 alkyl), having 1 to 3 carbon atoms (i.e., C 1~3 alkyl), or having 1 to 2 carbon atoms (i.e., C 1~2 alkyl). Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl group having a specific number of carbon atoms is designated by a chemical name or identified by a molecular formula, all positional isomers having that number of carbon atoms can be included; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0037] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkenyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkenyl), having 2 to 6 carbon atoms (i.e., C 2~6 alkenyl), or having 2 to 4 carbon atoms (i.e., C 2~4 Alkenyl refers to an aliphatic group. Examples of alkenyl groups are ethenyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0038] "Alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkynyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkynyl), having 2 to 6 carbon atoms (i.e., C 2~6 alkynyl), or having 2 to 4 carbon atoms (i.e., C 2~4 alkynyl), an aliphatic group. The term "alkynyl" also includes alkynyl groups having one triple bond and one double bond.

[0039] "Alkylene" refers to a divalent unbranched saturated hydrocarbon chain. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C 1~20 alkylene), having 1 to 12 carbon atoms (i.e., C 1~12 alkylene), having 1 to 8 carbon atoms (i.e., C 1~8 alkylene), having 1 to 6 carbon atoms (i.e., C 1~6 alkylene), having 1 to 4 carbon atoms (i.e., C 1~4 alkylene), having 1 to 3 carbon atoms (i.e., C 1~3 alkylene), or having 1 to 2 carbon atoms (i.e., C 1~2alkylene). Examples of alkylene groups include methylene, ethylene, propylene, butylene, pentylene, and hexylene. In some embodiments, alkylene is optionally substituted with an alkyl group. Substituted alkylene groups include -CH(CH3)CH2-, -CH2CH(CH3)-, -CH2CH(CH2CH3)-, -CH2C(CH3)2-, -C(CH3)2CH2-, -CH(CH3)CH(CH3)-, -CH2C(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2.

[0040] "Alkoxy" refers to an "alkyl-O-" group. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. "Haloalkoxy" refers to an alkoxy group, as defined above, in which one or more hydrogen atoms are replaced by halogen.

[0041] "Acyl" refers to the group -C(=O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which may be optionally substituted as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0042] "Amide" is -C(=O)NR y R z "C-amido" refers to the group, and -NR y C(=O)R z "N-amide group" refers to both the N-amide group and the N-amide group. y and R z is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is optionally substituted.

[0043] "Amino" is -NRy R z refers to a group, wherein R y and R z is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is optionally substituted.

[0044] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl refers to a group having 6 to 20 ring carbon atoms (i.e., C 6~20 aryl), having 6 to 12 carbon ring atoms (i.e., C 6~12 aryl), or having 6 to 10 carbon ring atoms (i.e., C 6~10 Aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. However, aryl does not encompass or overlap in any way with heteroaryl, as defined below. When one or more aryl groups are fused to a heteroaryl ring, the resulting ring system is heteroaryl.

[0045] "Cyano" or "carbonitrile" refers to the group --CN.

[0046] "Cycloalkyl" refers to saturated or partially saturated cyclic alkyl groups having single or multiple rings, including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkyl refers to groups having 3 to 20 ring carbon atoms (i.e., C 3~20 cycloalkyl), having 3 to 12 ring carbon atoms (i.e., C 3~12 cycloalkyl), having 3 to 10 ring carbon atoms (i.e., C 3~10 cycloalkyl), having 3 to 8 ring carbon atoms (i.e., C 3~8 cycloalkyl), or having 3 to 6 ring carbon atoms (i.e., C3~6 Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0047] "Cycloalkoxy" refers to the group "cycloalkyl-O-." Examples of cycloalkoxy groups include, but are not limited to: [ka]

[0048] "Bridged" refers to a ring fusion in which different atoms on the ring are joined by a divalent substituent such as an alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.

[0049] The term "fused" refers to rings that are joined to adjacent rings.

[0050] "Spiro" refers to a ring substituent joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, where cyclopentane and piperidine, respectively, are spiro substituents.

[0051] "Halogen" or "halo" includes fluoro, chloro, bromo, and iodo.

[0052] "Haloalkyl" refers to an unbranched or branched alkyl group, as defined above, in which one or more hydrogen atoms are replaced by halogen. For example, if a residue is substituted with two or more halogens, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0053] "Heteroalkylene" refers to a divalent unbranched saturated hydrocarbon chain having 1, 2, or 3 heteroatoms selected from NH, O, or S. As used herein, heteroalkylene refers to a heterocyclic group having 1 to 20 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~20 heteroalkylene; 1 to 8 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~8 heteroalkylene; 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~6 heteroalkylene; 1 to 4 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~4 heteroalkylene; 1 to 3 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3 heteroalkylene); or 1 to 2 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3Heteroalkylene groups include -CH2CHO-, -CH2SCH2-, -CH2CHOCH2-, -CH2NHCH2-, and -CH2NHCH2-. In some embodiments, heteroalkylene is optionally substituted with an alkyl group. Examples of substituted heteroalkylene groups include -CH(CH3)N(CH3)CH2-, -CHOCH(CH3)-, -CH2CH(CH2CH3)S-, -CH2NHC(CH3)2-, -C(CH3)2SCH2-, -CH(CH3)N(CH3)CH(CH3)O-, -CH2SC(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2NH-.

[0054] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl refers to a group having 1 to 20 carbon ring atoms (i.e., C 1~20 heteroaryl), 3 to 12 carbon ring atoms (i.e., C 3~12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3~8 Heteroaryl) and contains 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass and does not overlap with aryl, as defined above.

[0055] "Heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a non-aromatic cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a saturated or partially saturated ring unless otherwise specified. For example, in some embodiments, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a partially saturated ring when specified. The term "heterocyclyl" or "heterocyclic ring" or "heterocycle" includes heterocycloalkenyl groups (i.e., heterocyclyl groups having at least one double bond). Heterocyclyls may be monocyclic or polycyclic, and polycyclic rings may be fused, bridged, or spiro. As used herein, heterocyclyls have 2 to 20 carbon ring atoms (i.e., C 2~20 heterocyclyl), having 2 to 12 carbon ring atoms (i.e., C 2~12 heterocyclyl), having 2 to 10 carbon ring atoms (i.e., C 2~10 heterocyclyl), having 2 to 8 carbon ring atoms (i.e., C 2~8 heterocyclyl), having 3 to 12 carbon ring atoms (i.e., C 3~12 heterocyclyl), having 3 to 8 carbon ring atoms (i.e., C 3~8 heterocyclyl), or having 3 to 6 carbon ring atoms (i.e., C 3~6Heterocyclyl; having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term "bridged heterocyclyl" refers to a 4- to 10-membered ring moiety in which each heteroatom is independently connected to at least one heteroatom selected from nitrogen, oxygen, and sulfur at two non-adjacent atoms of a heterocyclyl having one or more (e.g., one or two) 4- to 10-membered ring moieties. As used herein, "bridged heterocyclyl" includes bicyclic and tricyclic ring systems. As used herein, the term "spiroheterocyclyl" refers to a ring system in which a 3- to 10-membered heterocyclyl has one or more additional rings, wherein the one or more additional rings are 3- to 10-membered cycloalkyl or 3- to 10-membered heterocyclyl, and a single atom of the one or more additional rings is also an atom of the 3- to 10-membered heterocyclyl. Examples of spiroheterocyclyls include bicyclic and tricyclic ring systems such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. As used herein, the terms "heterocycle," "heterocyclyl," and "heterocyclic ring" are used interchangeably. In some embodiments, the heterocyclyl is substituted with an oxo group.

[0056] "Heterocyclooxy" refers to the group "-O(heterocyclyl)". Examples of heterocyclooxy groups include, but are not limited to, -O(pyrrolidinyl), -O(tetrahydrofuranyl), -O(piperidinyl), -O(morpholinyl), -O(oxetanyl), and -O(2-oxa-7-azaspiro[3.5]nonanyl).

[0057] "Hydroxy" or "hydroxyl" refers to the group --OH.

[0058] "Oxo" refers to the (=O) or (O) radical.

[0059] "Sulfonyl" is -S(O)R bb refers to a group, wherein R bb is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0060] Whenever a group illustration terminates in a single bonded nitrogen atom, that group represents an -NH group unless otherwise indicated. Similarly, unless otherwise stated, hydrogen atoms are implied and considered to be present when needed to complete valence or provide stability, given the knowledge of those skilled in the art.

[0061] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances when the event or circumstance occurs and instances when the event or circumstance does not occur. Also, the term "optionally substituted" means that any one or more hydrogen atoms on a specified atom or group may or may not be replaced by a non-hydrogen moiety.

[0062] The term "substituted" means that any one or more hydrogen atoms on the specified atom or group are replaced with one or more substituents other than hydrogen, provided that the normal valence of the specified atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanato, thiol, thione, or combinations thereof. Polymers or similar amorphous structures resulting from defining the substituents with an infinite number of additional substituents (e.g., substituted aryls with substituted alkyls, which themselves are substituted with substituted aryl groups, which are further substituted with substituted heteroalkyl groups, etc.) are not intended to be included herein. Unless otherwise specified, the maximum number of consecutive substitutions in the compounds described herein is three. For example, consecutive substitution of a substituted aryl group with two other substituted aryl groups is limited to ((substituted aryl)substituted aryl)substituted aryl. Similarly, the above definition is not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluorines or a heteroaryl group having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to those of ordinary skill in the art. When used to modify a chemical group, the term "substituted" can describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl." Unless otherwise specified, if a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

[0063] In some embodiments, the substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and / or substituted heteroaryl includes a cycloalkyl, heterocyclyl, aryl, and / or heteroaryl having a substituent on a ring atom, where the cycloalkyl, heterocyclyl, aryl, and / or heteroaryl is attached to the remainder of the compound. For example, in the moiety below, the cyclopropyl is substituted with a methyl group: [ka]

[0064] The compounds of the embodiments disclosed herein, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, with respect to absolute stereochemistry, as (R)- or (S)-, or for amino acids, as (D)- or (L)-. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, these compounds are intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. When compounds are represented in their chiral form, it is understood that embodiments include, but are not limited to, the specific diastereomerically or enantiomerically enriched forms. Where chirality is not specified, it is understood that embodiments are directed to either the specific diastereomerically or enantiomerically enriched forms, or racemic or scalemic mixtures of such compounds. As used herein, a "scalemic mixture" is a mixture of stereoisomers in a ratio other than 1:1.

[0065] "Stereoisomers" refer to compounds made up of the same atoms connected by the same bonds but with different, not interchangeable, three-dimensional structures. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0066] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. A mixture of enantiomers in a ratio other than 1:1 is a "scalemic" mixture.

[0067] "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0068] "Tautomer" refers to a proton migration from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any compounds provided herein.

[0069] Some of the compounds provided herein exist as tautomeric isomers. Tautomeric isomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and regardless of the nature of the equilibrium between the tautomers, it is understood by those skilled in the art that the compound includes both the amide and imidic acid tautomers. Thus, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers.

[0070] A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds provided herein are also provided. Hydrates of the compounds provided herein are also provided.

[0071] Any formula or structure provided herein is also intended to represent unlabeled and isotopically labeled forms of the compound.Isotopically labeled compounds have the structure shown by the formula provided herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number.Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as:2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I. Various isotopically labeled compounds of the present disclosure include, but are not limited to, 2 H, 3 H, 13 C and 14 Also provided herein are compounds into which a radioactive isotope, such as C, is incorporated. Such isotopically labeled compounds may be useful in detection or imaging techniques such as metabolism studies, reaction kinetic studies, positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radiation treatment of patients.

[0072] The present disclosure also includes compounds of Formula I or II in which 1 to n hydrogens bonded to a carbon atom have been replaced by deuterium, where n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are therefore useful for extending the half-life of any compound of Formula I or II when administered to a mammal, particularly a human. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example, by employing starting materials in which one or more hydrogens have been replaced by deuterium.

[0073] Deuterium-labeled or deuterium-substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties related to absorption, distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes, such as deuterium, may confer certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, and / or improved therapeutic index. 18 F-labeled compounds can be useful in PET or SPECT studies.The isotopically labeled compounds of the present disclosure and their prodrugs can generally be prepared by replacing readily available isotopically labeled reagents with non-isotopically labeled reagents, and carrying out the procedures disclosed in the schemes or the examples and preparations described below.In this context, it is understood that deuterium is considered to be a substituent in the compound of formula I or II.

[0074] The concentration of such heavier isotopes, specifically deuterium, can be defined by the isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise specified, when a position is specifically designated as "H" or "hydrogen," the position is understood to have that hydrogen at the natural abundance isotopic composition of hydrogen. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is meant to represent deuterium.

[0075] In many cases, the compounds of the present disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0076] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dialkenylamines, trialkenylamines, substituted alkenylamines, di(substituted alkenyl)amines, tri(substituted alkenyl)amines, mono-, di-, or tricycloalkylamines, mono-, di-, or triarylamines, or mixed amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(iso-propyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0077] Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.

[0078] As used herein, "pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents. The use of such media and agents for pharmaceutically active substances is well known in the art. Except as far as any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0079] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include one or more of the following: a) inhibiting the disease or condition (i.e., reducing one or more symptoms resulting from the disease or condition and / or attenuating the severity of the disease or condition), b) slowing or arresting the onset of one or more clinical symptoms associated with the disease or condition (i.e., stabilizing the disease or condition, preventing or slowing the worsening or progression of the disease or condition, and / or preventing or slowing the spread (i.e., metastasis) of the disease or condition), and / or c) palliating the disease, i.e., causing regression of clinical symptoms (i.e., improving the disease state, providing partial or complete remission of the disease or condition, enhancing the effect of another drug, slowing the progression of the disease, improving quality of life, and / or prolonging survival).

[0080] "Prevention" or "preventing" means any treatment of a disease or condition that results in the non-development of clinical symptoms of the disease or condition. In some embodiments, the compounds may be administered to subjects (including humans) who are at risk or have a family history of the disease or condition.

[0081] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

[0082] The term "therapeutically effective amount" or "effective amount" of a compound described herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, means an amount sufficient to effect treatment and provide a therapeutic benefit, such as amelioration of symptoms or slowing of disease progression, when administered to a subject. For example, a therapeutically effective amount can be an amount sufficient to ameliorate the symptoms of a disease or condition in response to inhibition of toll-like receptors 7, 8, and / or 9. A therapeutically effective amount may vary depending on the subject, the disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the mode of administration, and can be readily determined by one of ordinary skill in the art. II. Compounds

[0083] In one embodiment, a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, During the ceremony, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl; wherein the 8- to 10-membered fused bicyclic heterocyclyl and the 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 4 R a and optionally substituted with a group, R 2 But H, C 1~6 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6The alkoxy is optionally substituted with 1 to 3 halogen groups; R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; C 1~4 the alkoxy is optionally substituted with 1 to 3 halogen groups; Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is C 1~6 Alkyl, C 2~6 Alkenyl, -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl and C 2~6 alkenyl, each independently, is selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from the group consisting of 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 But C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, R 13 But C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, R 7 But H, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 9 independently, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl, wherein C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a may be substituted with a group, Each R 5 and R 10 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is, each independently, 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R 11 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 11a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 12 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds having 1 to 4 ring heteroatoms, or a pharmaceutically acceptable salt thereof, wherein each 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl is independently selected from N, O, and S.

[0084] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally a is substituted with a group, R 2 But C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 7 is H or C1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , -NR 10 R 10 , -S(O)2R 5a , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 9 But independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 10 are independently H or a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a and optionally substituted with a group, Each R 5a are independently 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0085] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally a is substituted with a group, R 2 But C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, Each R 9 are independently a 4- to 7-membered monocyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently contain 1 to 4 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0086] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl and C 3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl; where C 1~6 Alkyl and C1~4 Alkoxy is, independently at each occurrence, —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 2 But C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 5~10bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 Alkyl is independently selected from -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , -NR10 R 10 , -S(O)2R 5a , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R 8b and optionally substituted with 1 to 3 groups independently selected from Each R 8a is independently a 4- to 7-membered monocyclic heterocyclyl or a 5- to 6-membered monocyclic heteroaryl; Each R 8b are independently 4- to 7-membered monocyclic heterocyclyl; Each R 9 But independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R 9a and optionally substituted with 1 to 3 groups independently selected from Each R 9a are independently 4- to 7-membered monocyclic heterocyclyl; Each R 10 are independently H or 4- to 7-membered monocyclic heterocyclyl; Each R 5a are independently 4- to 7-membered monocyclic heterocyclyl; Each R 11 However, independently, H, C 1~6 Alkyl or C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; Each R 11a But independently, C 1~4 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0087] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl and C 3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl; where C 1~6 Alkyl and C 1~4 Alkoxy is, independently at each occurrence, —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 2 But C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7, -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 Alkyl is independently selected from -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 7 is H or C 1~6 alkyl, where C1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 8a is a 4- to 7-membered monocyclic heterocyclyl; Each R 9 are independently 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 11 However, independently, H, C 1~6 Alkyl or C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; Each R 11a But independently, C 1~4 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0088] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally a is substituted with a group, R 2 But C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9, C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 to 4 R a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0089] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl and C3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl; where C 1~6 Alkyl and C 1~4 Alkoxy is, independently at each occurrence, —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 2 But C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 Alkyl is independently selected from -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 8a is a 4- to 7-membered monocyclic heterocyclyl; R 9 is a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 11 However, independently, H, C 1~6 Alkyl or C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0090] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally a is substituted with a group, R 2 But C 1~6 Alkyl, or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, or 8- to 10-membered fused bicyclic heteroaryl; 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a and optionally substituted with a group, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0091] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, -CN, oxo, halogen, C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 Monocyclic cycloalkyl, and -NR 11 R 11 and optionally substituted with 1 to 3 groups independently selected from where C 1~6 Alkyl and C 1~4 Alkoxy is, independently at each occurrence, —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 2 But C 1~6 Alkyl or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 monocyclic cycloalkyls each independently represent a halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) optionally substituted with 1 to 3 groups independently selected from Each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, or 8- to 10-membered fused bicyclic heteroaryl; wherein the 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of -OH, halogen, -CN, oxo, and -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; where C 1~4 Alkoxy and C 1~5Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; R 7 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 8a are independently 4- to 7-membered monocyclic heterocyclyl; R 9is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 11 However, independently, H, C 1~6 Alkyl or C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; Here, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0092] Unless otherwise specified, each 4-membered monocyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 5- to 7-membered monocyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 6-membered bridged bicyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 7-membered bridged bicyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl as used herein independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0093] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heterocyclyl and the 8- to 10-membered fused bicyclic heteroaryl each independently contain 1 to 4 R a is optionally substituted with a group.

[0094] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0095] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~6 and substituted with 1 to 3 groups independently selected from alkyl.

[0096] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heterocyclyl.

[0097] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~6 Alkyl, and C 3~7 and optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl, C 1~6 Alkyl and C 1~4 Alkoxy is each selected from -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0098] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a fused bicyclic heteroaryl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl, and C 3~7 substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl, wherein C 1~6 Alkyl and C 1~4Alkoxy is independently selected from the group consisting of —OH, halogen, —CN, and —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0099] In some embodiments of the compound of Formula I, the compound is a compound of Formula II: [ka] or a pharmaceutically acceptable salt thereof; During the ceremony, X 1 and X 2 However, each independently, CR 1a or N, R 1a , R 1b , and R 1c are each independently H, halogen, or C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 monocyclic cycloalkyl, or -N(R 14 )(R 14 ), where C 1~6 Alkyl and C 1~4 each alkoxy may be independently substituted with 1 to 3 halogen groups; Each R 14 However, independently, H, C 1~6 Alkyl, or C 3~7 It is a monocyclic cycloalkyl or a 4- to 7-membered monocyclic heterocyclyl.

[0100] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 1 is CR 1a or N. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 1 is CR 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 1 is CR 1a and R 1a is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X1 is N.

[0101] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 2 is CR 1a or N. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 2 is CR 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 2 is CR 1a and R 1a is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, X 2 is N.

[0102] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a , R 1b and R 1c are each independently H, halogen, or C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 Monocyclic cycloalkyl or -N(R 14 )(R 14 ), where C 1~6 Alkyl and C 1~4 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a , R 1b , and R 1c are each independently H, halogen, methyl, methoxy, —CF 3 , or CHF 2 .

[0103] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, each R 1a are independently H, halogen, C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 monocyclic cycloalkyl, or -N(R 14 )(R 14 ), where C 1~6Alkyl and C 1~4 Each alkoxy is independently optionally substituted with 1 to 3 halogen groups. In some embodiments of a compound of Formula II, or a pharmaceutically acceptable salt thereof, each R 1a is independently H, halogen, methyl, methoxy, —CF 3 , or CHF 2 . In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both of R 1a One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both of R 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both of R 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both of R 1a One or both of the following are C 1~4 Alkoxy, C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, one or both of R 1a One or both of the following are C 3~7 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1a One or both of the following is -N(R 14 )(R 14 )

[0104] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b H, halogen, C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 monocyclic cycloalkyl, or -N(R 14 )(R 14 ), where C 1~6 Alkyl and C 1~4 Each alkoxy is independently optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is H, halogen, methyl, methoxy, —CF 3 , or CHF 2 . In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is halogen. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is methyl. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is -CF3. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is CHF2. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is C 1~4 Alkoxy, C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is C 3~7In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1b is -N(R 14 )(R 14 )

[0105] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c H, halogen, C 1~6 Alkyl, C 1~4 Alkoxy, C 3~7 monocyclic cycloalkyl, or -N(R 14 )(R 14 ), where C 1~6 Alkyl and C 1~4 Each alkoxy is independently optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is H, halogen, methyl, methoxy, —CF or CHF. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is halogen. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is methyl. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is -CF3. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is CHF2. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is C 1~4 Alkoxy, C 1~4The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is C 3~7 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 1c is -N(R 14 )(R 14 )

[0106] In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, each R 14 are independently H, C 1~6 Alkyl, C 3~7 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 14 is H. In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 14 One or both of the following are C 1~6 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 14 One or both of the following are C 3~7 In some embodiments of the compound of Formula II, or a pharmaceutically acceptable salt thereof, R 14 One or both of the groups are 4- to 7-membered monocyclic heterocyclyl.

[0107] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] and Each of them is a halogen, C 1~3 Alkyl and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy, wherein C 1~3The alkyl is optionally substituted with 1 to 3 halogen groups.

[0108] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] and Halogen, C 1~3 Alkyl and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy, wherein C 1~3 The alkyl is optionally substituted with 1 to 3 halogen groups.

[0109] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] is.

[0110] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is the following equation: [ka]

[0111] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is the following equation: [ka]

[0112] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] and Each of them is a halogen, -CN, C 1~3 Alkyl and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0113] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 1 is the following equation: [ka]

[0114] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is H, C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is H, C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is H, C 1~6 Alkyl or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~7The monocyclic cycloalkyls each independently represent a halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0115] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 Alkyl or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 Alkyl or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 Alkyl or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0116] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 Alkyl, or C 3~5 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 3~5 The monocyclic cycloalkyls each independently represent a halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0117] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 It is alkyl.

[0118] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, where C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, where C 1~6 Alkyl is halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 It is alkyl.

[0119] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0120] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 and substituted with 1 to 3 groups independently selected from alkoxy.

[0121] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1-4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is ethyl or isopropyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is methyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is isopropyl.

[0122] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~6The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0123] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~7 It is a monocyclic cycloalkyl.

[0124] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~3 substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0125] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~5 is a monocyclic cycloalkyl, C 3~5 Monocyclic cycloalkyl is substituted with halogen and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 3~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is cyclopropyl.

[0126] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 2 is isopropyl or cyclopropyl.

[0127] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H, halogen, -CN, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0128] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H or C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H or C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H or methyl.

[0129] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is halogen. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is -CN.

[0130] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7may be substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; 1~4 The alkoxy may be substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; 1~4 The alkoxy may be substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 3~7 It is a monocyclic cycloalkyl.

[0131] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocyclooxy; 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocyclooxy; 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is a 4- to 7-membered monocyclic heterocyclyl.

[0132] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 may be substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; 1~4 The alkoxy may be substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, -C(O)N(R 4 )2, 4- to 7-membered monocyclic heterocyclyl, C 3~7 substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy and 4- to 7-membered monocyclic heterocycloxy; 1~4 The alkoxy may be substituted with 1 to 3 halogen groups.

[0133] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, where C 1~6Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, C 1~4 Alkoxy, -C(O)C 1~6 Alkyl, and -C(O)N(R 4 ) substituted with 1 to 3 groups independently selected from 2.

[0134] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 -OH, halogens, -CN and C 1~3 C optionally substituted with 1 to 3 groups independently selected from alkoxy 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is methyl substituted with 1 to 3 halogen groups. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is -CHF2.

[0135] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is methyl.

[0136] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 3 is H, methyl, -CHF2, -CH2OH, -CH2OCH3 or ethyl.

[0137] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 4 are independently H or C 1~6 alkyl, or both R 4 together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R 4 is H. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R 4 is C 1~6 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, both R 4 taken together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl.

[0138] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 1~6 Alkyl, C 2~6 Alkenyl, -C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl and C 2~6alkenyl, each independently, is selected from 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0139] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0140] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0141] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0142] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0143] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0144] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, or 8- to 10-membered fused bicyclic heteroaryl; 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0145] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , C 3~7 Monocyclic cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent one to two R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0146] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 , -C(O)NR 6 R 7 , -S(O)2R 6 , 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, or 8- to 10-membered fused bicyclic heteroaryl; wherein the 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of -OH, halogen, -CN, oxo, and -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0147] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0148] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10 The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent one to two R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0149] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 1~6 alkyl, C 1~6 The alkyl may optionally contain 1 to 4 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 alkyl, C 1~6 The alkyl may optionally contain 1 to 3 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 alkyl, C 1~6 Alkyl is 1 to 4 Rb In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 alkyl, C 1-10 Alkyl has 1 to 3 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 It is alkyl.

[0150] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 2~6 alkenyl, C 2~6 The alkenyl optionally has 1 to 4 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2~6 alkenyl, C 2~6 The alkenyl optionally has 1 to 3 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2~6 alkenyl, C 2~6 Alkenyl has 1 to 4 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2~6 alkenyl, C 2~6 Alkenyl has 1 to 3 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 2-6 It is alkenyl.

[0151] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 optionally substituted with a group and 1 to 3 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0152] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0153] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7Monocyclic cycloalkyl has 1 to 2 R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0154] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from C 3~7 It is a monocyclic cycloalkyl.

[0155] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is selected from the group consisting of 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1 to 3 groups independently selected from R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1 to 3 groups independently selected from R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, which are each substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0156] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group.7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 It is a fused bicyclic cycloalkyl.

[0157] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0158] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0159] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0160] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10A bridged bicyclic cycloalkyl is one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyls include -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from C 5~10 It is a bridged bicyclic cycloalkyl.

[0161] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0162] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and This can optionally be one R 8 is substituted with a group.

[0163] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and This can optionally be one R 8 is substituted with a group.

[0164] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl.

[0165] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0166] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0167] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0168] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0169] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 optionally substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0170] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0171] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0172] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from one to two R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with one to three R groups. aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, and phenyl is optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0173] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is selected from one to two R 8 optionally substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, which is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0174] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, which is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0175] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, which is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0176] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, and the naphthalenyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, which is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is naphthalenyl, wherein naphthalenyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0177] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from one to two R 8optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is optionally substituted with one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, wherein the 5- to 6-membered monocyclic heteroaryl is substituted with one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, wherein the 5-6 membered monocyclic heteroaryl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl.

[0178] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0179] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0180] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0181] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is selected from one to two R 8In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, and the 6-membered monocyclic heteroaryl is substituted with one to three R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6-membered monocyclic heteroaryl, wherein the 6-membered monocyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0182] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0183] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0184] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0185] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is substituted with one to three R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl.

[0186] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0187] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0188] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0189] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0190] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0191] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0192] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0193] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl, wherein the 7-8 membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-8 membered bridged bicyclic heterocyclyl.

[0194] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0195] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0196] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from one to two R 8 substituted with 1 to 3 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0197] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl.

[0198] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0199] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0200] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from one to two R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is substituted with one to two R groups. 8 and substituted with -OH, halogen, -CN, oxo, -NR11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0201] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is substituted with one to three R groups. a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl.

[0202] In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; wherein the 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of -OH, halogen, -CN, oxo, and -NR 11 R 11 , C1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0203] In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; wherein the 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of -OH, halogen, -CN, oxo, and -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; The 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently have 1 or 2 ring heteroatoms which are N.

[0204] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heterocyclyl; 5-6 membered monocyclic heterocyclyl is one or two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; A 5-6 membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0205] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is pyrrolidinyl or piperidinyl, each of which is selected from the group consisting of 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0206] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is piperidinyl, which optionally has one R 8 is substituted with a group.

[0207] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 and azetidinyl optionally substituted with a group.

[0208] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is azepanyl, which optionally contains one R 8 is substituted with a group.

[0209] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, naphthalenyl, or 6-membered monocyclic heteroaryl, each of which is selected from 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0210] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl, pyridinyl, or pyrimidinyl, each of which is selected from the group consisting of one R8 is optionally substituted with a group.

[0211] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is phenyl or pyridinyl, each of which is selected from the group consisting of one R 8 is optionally substituted with a group.

[0212] In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl, each of which is selected from the group consisting of 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0213] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0214] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z optionally contains 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5and 6- to 10-membered bridged bicyclic heterocyclyl substituted with 1 to 2 groups independently selected from alkyl.

[0215] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z optionally contains 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and a 7- to 8-membered bridged bicyclic heterocyclyl substituted with 1 to 2 groups independently selected from alkyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0216] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z optionally contains 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and 7-10 membered spirocyclic heterocyclyl substituted with 1 to 2 groups independently selected from alkyl.

[0217] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and a 7- to 10-membered spirocyclic heterocyclyl optionally substituted with 1 to 2 R groups, each of which is optionally substituted with 1 to 2 groups independently selected from alkyl, wherein the 7- to 10-membered spirocyclic heterocyclyl has 1 or 2 ring heteroatoms independently selected from N and O.

[0218] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0219] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0220] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0221] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0222] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0223] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] Each of these is one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0224] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these has 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0225] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these optionally contains one R 8 is substituted with a group.

[0226] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these optionally contains one R 8 is substituted with a group.

[0227] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, Z is [ka] and Each of these optionally contains one R 8 is substituted with a group.

[0228] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0229] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0230] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0231] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0232] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0233] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0234] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R8 Z substituted with a group is of the formula: [ka]

[0235] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0236] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0237] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0238] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0239] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0240] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0241] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0242] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0243] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0244] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0245] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8Z substituted with a group is of the formula: [ka]

[0246] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0247] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0248] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0249] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0250] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0251] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0252] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0253] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0254] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0255] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0256] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0257] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is of the formula: [ka]

[0258] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R5a ), -OC(O)R 5 , -OC(O)OR 5 , -OC(O)N(R 5 )(R 5 ), -SR 5 , -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0259] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , -NR 10 R 10 , -S(O)2R 5a , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0260] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0261] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , -NR 10 R 10 , -S(O)2R 5a , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R 8b and optionally substituted with 1 to 3 groups independently selected from:

[0262] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0263] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1~6Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0264] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8a is independently a 4- to 7-membered monocyclic heterocyclyl or a 5- to 6-membered monocyclic heteroaryl.

[0265] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8a is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8a is a 5- to 6-membered monocyclic heteroaryl.

[0266] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8b are independently 4- to 7-membered monocyclic heterocyclyl.

[0267] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8b is a 4- to 7-membered monocyclic heterocyclyl.

[0268] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both of R 8 Either one or both of the following is -OR 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -C(O)OR 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are -C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )2(R 5 ) + In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )C(O)R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )C(O)OR 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )S(O)2(R 5a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -NR 5 S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -NR5 S(O)2O(R 5a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -OC(O)R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of these are -OC(O)OR 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are -OC(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -SR 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -S(O)R 5a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are -S(O)(NH)R 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are -S(O)R 5a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of -S(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of -N=S(R 5a )(R 5a )=O.

[0269] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl may optionally contain 1 to 4 Rb In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 (R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 ,-C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 (R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4 to 7-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a, -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 It is optionally substituted with 1 to 3 groups independently selected from alkoxy and 4- to 7-membered monocyclic heterocyclyl.

[0270] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 (R 11 ), C 1~4 Alkoxy, and R8a In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, 4 to 7-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 is C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , C 1~4In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 5-membered monocyclic heterocyclyl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 5-membered monocyclic heterocyclyl. 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a and 4- to 5-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, where C 1~6The alkyl is substituted with one to three groups independently selected from -OH, -CN, oxo, -NH, -N(CH), -C(O)(azetidinyl), -C(O)OH, -C(O)OCH(CH), -C(O)NH, -C(O)NH, -C(O)NH(CH), -C(O)NH(CHCH), -C(O)NH(CH(CH)), -C(O)NH(cyclopropyl), -C(O)NH(oxetanyl), -C(O)N(CH), -S(O)CH, -S(O)NH, -S(O)NH(CH), -S(O)N(CH), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), -S(O)CH, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -S(O)2CH3, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~3 alkyl, where C 1~3 The alkyl is substituted with one group independently selected from -C(O)NH and -C(O)NHCH. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is a methyl substituted with one -C(O)NH2 group.

[0271] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, -S(O)2CH3, oxetanyl, and pyrrolidinyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, oxetanyl, and pyrrolidinyl.

[0272] In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R 8 is C 1~6 alkyl, C 1~6 The alkyl may optionally contain 1 to 4 R b In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R 8 is C 1~6 alkyl, C 1~6 The alkyl may optionally contain 1 to 3 R bIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4 to 7-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl. 8 One or both of the following are C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), -S(O)CH, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), -S(O)CH, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -S(O)2CH3, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, and oxetanyl.

[0273] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3Alkyl is -OH, halogen, -CN, oxo, NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4 to 7-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl. 8 One or both of the following are C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3The alkyl is optionally substituted with one group independently selected from -C(O)NH and -C(O)NHCH. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is methyl optionally substituted with one -C(O)NH2 group.

[0274] In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both R 8 is C 1~6 alkyl, C 1~6 Alkyl is 1 to 4 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 Alkyl has 1 to 3 R b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from 4- to 7-membered monocyclic heterocyclyl, and 5- to 6-membered monocyclic heteroaryl. 8 One or both of the following are C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~6 alkyl, C 1~6 Alkyl is -OH, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a and 4- to 5-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6The alkyl is substituted with one to three groups independently selected from -OH, -CN, oxo, -NH, -N(CH), -C(O)(azetidinyl), -C(O)OH, -C(O)OCH(CH), -C(O)NH, -C(O)NH, -C(O)NH(CH), -C(O)NH(CHCH), -C(O)NH(CH(CH)), -C(O)NH(cyclopropyl), -C(O)NH(oxetanyl), -C(O)N(CH), -S(O)CH, -S(O)NH, -S(O)NH(CH), -S(O)N(CH), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), -S(O)CH, and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), and 4-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -S(O)2CH3, and oxetanyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, and oxetanyl.

[0275] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, 4 to 7-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl. 8 One or both of the following are C 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , -S(O)2N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), -S(O)R 11a , C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy, and 4- to 7-membered monocyclic heterocyclyl. 8 One or both of the following are C 1~3 alkyl, C 1~3 Alkyl is -OH, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O)2R 11a , -S(O)2N(R11 )(R 11 ), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6 Alkyl is -OH, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , -S(O)2R 11a and 4- to 5-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3 Alkyl is oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, C 1~3 The alkyl is substituted with one to three groups independently selected from -OH, -CN, oxo, NH, -N(CH), -C(O)(azetidinyl), -C(O)OH, -C(O)OCH(CH), -C(O)NH, -C(O)NH, -C(O)NH(CH), -C(O)NH(CHCH), -C(O)NH(CH(CH)), -C(O)NH(cyclopropyl), -C(O)NH(oxetanyl), -C(O)N(CH), -S(O)CH, -S(O)NH, -S(O)NH(CH), -S(O)N(CH), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of1~3 alkyl, where C 1~3 Alkyl is -OH, -CN, oxo, pyrrolidinyl, [ka] is substituted with 1 to 3 groups independently selected from

[0276] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 alkyl, where C 1~3 The alkyl is substituted with one group independently selected from -C(O)NH and -C(O)NHCH. In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is methyl substituted with one —C(O)NH group. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~3 It is alkyl.

[0277] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, C 1~6 The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, -S(O)2CH3, oxetanyl, and pyrrolidinyl. In some embodiments of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 1~6 alkyl, where C 1~6The alkyl is substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, oxetanyl, and pyrrolidinyl.

[0278] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 3~7 It is a monocyclic cycloalkyl.

[0279] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 7~10 is a fused bicyclic cycloalkyl, C 7~10 The fused bicyclic cycloalkyl optionally contains 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 7~10 is a fused bicyclic cycloalkyl, C 7~10 Fused bicyclic cycloalkyl is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 7~10 It is a fused bicyclic cycloalkyl.

[0280] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 5~10 Bridged bicyclic cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl optionally contains 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following are C 5~10 It is a bridged bicyclic cycloalkyl.

[0281] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 4- to 7-membered monocyclic heterocyclyls optionally contain 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 4- to 7-membered monocyclic heterocyclyl groups optionally having 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0282] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 4- to 7-membered monocyclic heterocyclyl groups are 4 to 7-membered monocyclic heterocyclyl groups, and the 4 to 7-membered monocyclic heterocyclyl group is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 4- to 7-membered monocyclic heterocyclyl groups are 4- to 7-membered monocyclic heterocyclyl groups, and the 4- to 7-membered monocyclic heterocyclyl group is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0283] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8One or both of the groups are 4- to 7-membered monocyclic heterocyclyl.

[0284] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heterocyclyl groups are 5- to 6-membered monocyclic heterocyclyl groups, and the 5- to 6-membered monocyclic heterocyclyl group is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heterocyclyl groups are 5- to 6-membered monocyclic heterocyclyl groups, and the 5- to 6-membered monocyclic heterocyclyl group is 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the groups are 5- to 6-membered monocyclic heterocyclyl, where the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0285] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heterocyclyl groups are 5- to 6-membered monocyclic heterocyclyl groups, and the 5- to 6-membered monocyclic heterocyclyl group is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heterocyclyl groups are 5- to 6-membered monocyclic heterocyclyl groups, and the 5- to 6-membered monocyclic heterocyclyl group is 1 to 3 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0286] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 5- to 6-membered monocyclic heterocyclyl.

[0287] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the groups are phenyl, and the phenyl is substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the groups are phenyl, and the phenyl is substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of are phenyl.

[0288] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is naphthalenyl, and the naphthalenyl optionally has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the groups are naphthalenyl, and the naphthalenyl is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are naphthalenyl.

[0289] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 5- to 6-membered monocyclic heteroaryl, where the 5- to 6-membered monocyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b and optionally substituted with 1 to 3 groups independently selected from:

[0290] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 5- to 6-membered monocyclic heteroaryl, where the 5- to 6-membered monocyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b is substituted with 1 to 3 groups independently selected from

[0291] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 5- to 6-membered monocyclic heteroaryl.

[0292] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the above are 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0293] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the above are 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0294] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 8-10 membered fused bicyclic heterocyclyl.

[0295] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0296] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8or both of are 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0297] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 6- to 10-membered bridged bicyclic heterocyclyl.

[0298] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is aIn some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0299] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of are 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both of the 7- to 8-membered bridged bicyclic heterocyclyl, wherein the 7- to 8-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0300] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 7-8 membered bridged bicyclic heterocyclyl.

[0301] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8one or both of the 7- to 10-membered spirocyclic heterocyclyl groups are optionally substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b and optionally substituted with 1 to 3 groups independently selected from:

[0302] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 one or both of the 7- to 10-membered spirocyclic heterocyclyls are 7- to 10-membered spirocyclic heterocyclyls, and the 7- to 10-membered spirocyclic heterocyclyls are 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b is substituted with 1 to 3 groups independently selected from

[0303] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are 7-10 membered spirocyclic heterocyclyl.

[0304] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 is independently a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0305] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 is independently a 4- to 7-membered monocyclic heterocyclyl or a 6- to 10-membered bridged bicyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; wherein the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each independently have 1 or 2 ring heteroatoms independently selected from N and S.

[0306] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently a 5- to 6-membered monocyclic heterocyclyl or a 7- to 8-membered bridged bicyclic heterocyclyl; The 5- to 6-membered monocyclic heterocyclyl and the 7- to 8-membered bridged bicyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0307] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8are independently selected from oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, [ka] and Each of these is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0308] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently selected from oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, [ka] and Each of these is optionally substituted with 1 to 3 groups independently selected from halogen and oxo.

[0309] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently piperazinyl, [ka] and Each of these is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0310] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 is independent, [ka] and Each is substituted with 1 to 2 oxo groups.

[0311] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 is independent, [ka] and Each is substituted with 1 to 2 oxo groups.

[0312] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently: [ka]

[0313] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently: [ka]

[0314] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently 7-10 membered spirocyclic heterocyclyl, where the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0315] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8is independently a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with 1 to 3 oxo groups.

[0316] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently: [ka]

[0317] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently: [ka]

[0318] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently 5-6 membered monocyclic heteroaryl, where the 5-6 membered monocyclic heteroaryl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 8b and optionally substituted with 1 to 3 groups independently selected from:

[0319] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 are independently 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is 8b is optionally substituted with

[0320] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8 is independent, [ka] and Each of these optionally contains one R 8b is replaced by .

[0321] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8b are independently 6- to 7-membered monocyclic heterocyclyl.

[0322] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8b is independently a 6-membered monocyclic heterocyclyl.

[0323] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 8b are independently morpholinyl.

[0324] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 is -C(O)R 9 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -C(O)R 9 is.

[0325] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 independently, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0326] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 But independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 The monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0327] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 are independently a 4- to 7-membered monocyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each have 1 to 4 R a is optionally substituted with a group.

[0328] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 are independently 4- to 7-membered monocyclic heterocyclyl or 6- to 10-membered bridged bicyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl each have 1 to 4 R a is optionally substituted with a group.

[0329] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 But independently, C 3~7 monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, 3~7 Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, c 1~5 Alkyl, and R 9a and optionally substituted with 1 to 3 groups independently selected from:

[0330] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9a are independently 4- to 7-membered monocyclic heterocyclyl.

[0331] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9 are independently 4- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0332] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R 9are independently 4- to 7-membered monocyclic heterocyclyl or 6- to 10-membered bridged bicyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0333] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group consisting of 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl, and R9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 3~7 It is a monocyclic cycloalkyl.

[0334] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 7~10 is a fused bicyclic cycloalkyl, C 7~10 The fused bicyclic cycloalkyl optionally contains 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 7~10 is a fused bicyclic cycloalkyl, C 7~10 Fused bicyclic cycloalkyl is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 7~10 It is a fused bicyclic cycloalkyl.

[0335] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 5~10 Bridged bicyclic cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl optionally contains 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the following are C 5~10 It is a bridged bicyclic cycloalkyl.

[0336] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the groups are phenyl, and the phenyl is substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the groups are phenyl, and the phenyl is substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are phenyl.

[0337] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl, and the naphthalenyl optionally has 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the groups are naphthalenyl, and the naphthalenyl is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are naphthalenyl.

[0338] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9One or both of the groups are 5- to 6-membered monocyclic heteroaryl.

[0339] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 8-10 membered fused bicyclic heterocyclyl.

[0340] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9one or both of the 8- to 10-membered fused bicyclic heteroaryl is an 8- to 10-membered fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 8- to 10-membered fused bicyclic heteroaryl is an 8- to 10-membered fused bicyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 8-10 membered fused bicyclic heteroaryl.

[0341] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 7- to 10-membered spirocyclic heterocyclyl groups are optionally substituted with 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkyl. 9or both are 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 7- to 10-membered spirocyclic heterocyclyls are 7- to 10-membered spirocyclic heterocyclyls, and the 7- to 10-membered spirocyclic heterocyclyls are 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both are 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both are 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 7-10 membered spirocyclic heterocyclyl.

[0342] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 4- to 7-membered monocyclic heterocyclyl groups are 4 to 7-membered monocyclic heterocyclyl groups, and the 4 to 7-membered monocyclic heterocyclyl group is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 4- to 7-membered monocyclic heterocyclyls are 4- to 7-membered monocyclic heterocyclyls, and the 4- to 7-membered monocyclic heterocyclyls are 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 7-membered monocyclic heterocyclyl, where the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 4- to 7-membered monocyclic heterocyclyl.

[0343] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 5- to 7-membered monocyclic heterocyclyl groups are 5- to 7-membered monocyclic heterocyclyl groups, and the 5- to 7-membered monocyclic heterocyclyl group is 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 5- to 7-membered monocyclic heterocyclyl, where the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 5- to 7-membered monocyclic heterocyclyl, where the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 5- to 7-membered monocyclic heterocyclyls are 5- to 7-membered monocyclic heterocyclyls, and the 5- to 7-membered monocyclic heterocyclyls are 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 5- to 7-membered monocyclic heterocyclyl, where the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 5- to 7-membered monocyclic heterocyclyl, where the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 5- to 7-membered monocyclic heterocyclyl.

[0344] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 one or both of the 4- to 6-membered monocyclic heterocyclyl groups are 4 to 6-membered monocyclic heterocyclyl groups, and the 4 to 6-membered monocyclic heterocyclyl group is a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, one or both of R9 is a 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4Alkoxy, C 1~5 Alkyl and R 9a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 6-membered monocyclic heterocyclyl, where the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkyl. 9 or both are 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 2 groups independently selected from alkyl. 9 one or both of the 4- to 6-membered monocyclic heterocyclyls are 4- to 6-membered monocyclic heterocyclyls, and the 4- to 6-membered monocyclic heterocyclyls are 1 to 4 R a In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, R 9 or both of the groups are 4- to 6-membered monocyclic heterocyclyl, where the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 Alkyl and R 9a In some...

Claims

1. A compound of formula I, 【Chemical 274】 or a pharma- ceutically acceptable salt thereof, During the ceremony, R １ is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heterocyclyl and the 8- to 10-membered fused bicyclic heteroaryl each independently comprise 1 to 4 R ａ is optionally substituted with a group; R ２ But, H, C １～６ Alkyl, or C ３～７ is a monocyclic cycloalkyl; １～６ Alkyl and C ３～７ Each monocyclic cycloalkyl is independently selected from halogen and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Said C １～６ the alkoxy is optionally substituted with 1 to 3 halogen groups; R ３ is H, halogen, -CN, C １～６ Alkyl, C ３～７ monocyclic cycloalkyl, or 4- to 7-membered monocyclic heterocyclyl; Said C １～６ Alkyl, C ３～７ Monocyclic cycloalkyl and 4- to 7-membered monocyclic heterocyclyl are each independently -OH, halogen, -CN, C １～４ Alkoxy, -C(O)C １～６ Alkyl, -C(O)N(R ４ ) ２ , 4- to 7-membered monocyclic heterocyclyl, C ３～７ optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkoxy, and 4- to 7-membered monocyclic heterocyclooxy; Said C １～４ the alkoxy is optionally substituted with 1 to 3 halogen groups; Each R ４ are independently H or C １～６ alkyl or both R ４ together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is C １～６ Alkyl, C ２～６ Alkenyl, -C(O)R １３ , -C(O)NR ６ R ７ , -S(O) ２ R ６ , C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl and C ２～６ alkenyl, each independently, is 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 2 R ８ groups, each independently being 1 to 3 R ａ is optionally substituted with a group; R ６ But, C １～６ Alkyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; R １３ But, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; R ７ But, H, C １～６ Alkyl, C ３～７ monocyclic cycloalkyl, or 4- to 6-membered monocyclic heterocyclyl, １～６ Alkyl, C ３～７ The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R ８ are independently halogen, —C(O)R ９ , -NR １０ R １０ , C １～６ Alkyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR ５ , -C(O)OR ５ , -C(O)N(R ５ ) (R ５ ), -N(R ５ ) ２ (R ５ ) ＋ , -N(R ５ ) C(O)R ５ , -N(R ５ ) C(O)OR ５ , -N(R ５ ) C(O)N(R ５ ) (R ５ ), -N(R ５ ) S (O) ２ (R ５ａ ), -NR ５ S (O) ２ N (R ５ ) (R ５ ), -NR ５ S (O) ２ O (R ５ａ ), -OC(O)R ５ , -OC(O)OR ５ , -OC(O)N(R ５ ) (R ５ ), -SR ５ , -S(O)R ５ａ , -S(O)(NH)R ５ , -S(O) ２ R ５ａ , -S(O) ２ N (R ５ ) (R ５ ), or -N=S(R ５ａ ) (R ５ａ )=O, Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ９ But, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ５ and R １０ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently selected from 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ５ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently selected from 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ａ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is, independently at each occurrence, 1 to 3 R ｃ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｂ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｃ are independently halogen, -CN, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ -S(O)(NH)R １２ , -S(O) ２ R １２ａ , -S(O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Each R ｄ are independently oxo, halogen, -CN, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ , -S(O)(NH)R １２ , -S(O) ２ R １２ａ , -S(O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Each R １１ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １１ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １２ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Each R １２ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; A compound of Formula I, or a pharma- ceutically acceptable salt thereof, wherein each of the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl independently has from 1 to 4 ring heteroatoms independently selected from N, O, and S;

2. Z is C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; Said C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ 5-membered fused bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R ８ groups, each independently being 1 to 3 R ａ or Z is -C(O)R 13 , -C(O)NR 6 R 7 , -S(O) 2 R 6 , C 3-7 monocyclic cycloalkyl, C 5-10 bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl or 7-10 membered spirocyclic heterocyclyl; said C 3-7 monocyclic cycloalkyl, C 5-10 bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each independently optionally substituted with one to two R 8 groups, and each independently optionally substituted with one to three R a groups; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

3. R １ is an 8-10 membered fused bicyclic heteroaryl, said 8-10 membered fused bicyclic heteroaryl optionally having 1 to 4 R ａ is substituted with a group, R ２ But, C １～６ Alkyl, or C ３～７ is a monocyclic cycloalkyl; １～６ Alkyl and C ３～７ Each monocyclic cycloalkyl is independently selected from halogen and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; R ３ is H or C １～６ alkyl, １～６ Alkyl is -OH, halogen, -CN, C １～４ Alkoxy, -C(O)C １～６ Alkyl, and -C(O)N(R ４ ) ２ and optionally substituted with 1 to 3 groups independently selected from Each R ４ are independently H or C １～６ alkyl or both R ４ together with the nitrogen to which they are attached form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R １３ , -C(O)NR ６ R ７ , -S(O) ２ R ６ , C ３～７ Monocyclic cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C ３～７ Monocyclic cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 2 R ８ groups, each independently being 1 to 3 R ａ is optionally substituted with a group; R ６ is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl being represented by 1 to 4 R ａ is optionally substituted with a group; R １３ is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl being represented by 1 to 4 R ａ is optionally substituted with a group; R ７ is H or C １～６ alkyl, where C １～６ Alkyl is -OH, halogen, -CN and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R ８ are independently -C(O)R ９ , -NR １０ R １０ , -S(O) ２ R ５ａ , C １～６ alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R ａ is optionally substituted with a group; Each R ９ But independently, C ３～７ monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl, ３～７ Monocyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R １０ are independently H or a 4- to 7-membered monocyclic heterocyclyl, the 4- to 7-membered monocyclic heterocyclyl being one to four R ａ is optionally substituted with a group; Each R ５ａ is independently 4- to 7-membered monocyclic heterocyclyl, the 4- to 7-membered monocyclic heterocyclyl being selected from 1 to 4 R ａ is optionally substituted with a group; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; wherein the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S; or R 1 is an 8-10 membered fused bicyclic heteroaryl, wherein said 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, C 1-6 alkyl, and C 3-7 monocyclic cycloalkyl; wherein C 1-6 alkyl and C 1-4 alkoxy are each independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN and -NR 12 R 12 ; R 2 is C 1-6 alkyl, or C 3-5 monocyclic cycloalkyl, wherein said C 1-6 alkyl and C 3-5 monocyclic cycloalkyl are each optionally substituted with 1 to 4 groups independently selected from halogen and C 1-6 alkoxy; R 3 is H or C 1-6 alkyl, said C 1-6 alkyl being optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, C 1-4 alkoxy, -C(O)C 1-6 alkyl, and -C(O)N(R 4 ) 2 ; each R 4 is independently H or C 1-6 alkyl, or both R 4 , together with the nitrogen to which they are attached, form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R13, ​​-C(O)NR6R7, -S(O)2R6, C3-7 monocyclic cycloalkyl, C5-10 bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, or 7-10 membered spirocyclic heterocyclyl; said C 3-7 monocyclic cycloalkyl, C 5-10 bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenylphenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl are each independently optionally substituted with one to two R 8 groups, and each independently optionally substituted with one to three groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl, said C 1-4 alkoxy and C 1-5 alkyl each independently being substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, and -NR 12 R 12 ; R 13 is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; R 7 is H or C 1-6 alkyl, wherein said C 1-6 alkyl is optionally substituted with 1 to 4 groups independently selected from -OH, halogen, -CN and C 1-6 alkoxy; each R 8 is independently -C(O)R 9 , -NR 10 R 10 , -S(O) 2 R 5a , C 1-6 alkyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, or 7- to 10-membered spirocyclic heterocyclyl; said C 1-6 alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O) 2 R 11a , -S(O) 2 N(R 11 )(R 11 ), C 1-4 alkoxy, and R 8a ; said 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, C 1-5 alkyl, and R 8b ; each R 8a is independently 4- to 7-membered monocyclic heterocyclyl or 5- to 6-membered monocyclic heteroaryl; each R 8b is independently 4- to 7-membered monocyclic heterocyclyl; each R 9 is independently a C 3-7 monocyclic cycloalkyl, a 4-7 membered monocyclic heterocyclyl, an 8-10 membered fused bicyclic heterocyclyl, a 6-10 membered bridged bicyclic heterocyclyl, or a 7-10 membered spirocyclic heterocyclyl, wherein said C 3-7 monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, and 7-10 membered spirocyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, C 1-5 alkyl, and R 9a ; each R 9a is independently 4- to 7-membered monocyclic heterocyclyl; each R 10 is independently H or a 4- to 7-membered monocyclic heterocyclyl; each R 5a is independently 4- to 7-membered monocyclic heterocyclyl; each R 11 is independently H, C 1-6 alkyl, or C 3-7 monocyclic cycloalkyl, or 4- to 7-membered monocyclic heterocyclyl; each R 11a is independently C 1-4 alkyl; each R 12 is independently H or C 1-4 alkyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; wherein the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S; or R 1 is an 8-10 membered fused bicyclic heteroaryl, said 8-10 membered fused bicyclic heteroaryl optionally substituted with 1-4 R a groups; R 2 is C 1-6 alkyl, or C 3-7 monocyclic cycloalkyl, wherein said C 1-6 alkyl and C 3-7 monocyclic cycloalkyl are each optionally substituted with 1 to 4 groups independently selected from halogen and C 1-6 alkoxy; R 3 is H or C 1-6 alkyl, said C 1-6 alkyl being optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, C 1-4 alkoxy, -C(O)C 1-6 alkyl, and -C(O)N(R 4 ) 2 ; each R 4 is independently H or C 1-6 alkyl, or both R 4 , together with the nitrogen to which they are attached, form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R13, ​​-C(O)NR6R7, -S(O)2R6, a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; said 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl are each independently optionally substituted with one to two R 8 groups, and each independently optionally substituted with one to three R a groups; R 6 is 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl optionally substituted with 1 to 4 R a groups; R 13 is 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl optionally substituted with 1 to 4 R a groups; R 7 is H or C 1-6 alkyl, wherein said C 1-6 alkyl is optionally substituted with 1 to 4 groups independently selected from -OH, halogen, -CN and C 1-6 alkoxy; each R 8 is independently -C(O)R 9 , C 1-6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; said C 1-6 alkyl is optionally substituted with 1 to 4 R b groups; said 4- to 7-membered monocyclic heterocyclyl and 6- to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 4 R a groups; R 9 is 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl optionally substituted with 1 to 4 R a groups; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; wherein the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S; or R 1 is an 8-10 membered fused bicyclic heteroaryl, wherein said 8-10 membered fused bicyclic heteroaryl is optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, C 1-6 alkyl, and C 3-7 monocyclic cycloalkyl; wherein said C 1-6 alkyl and C 1-4 alkoxy are each independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN and -NR 12 R 12 ; R 2 is C 1-6 alkyl, or C 3-5 monocyclic cycloalkyl, wherein said C 1-6 alkyl and C 3-5 monocyclic cycloalkyl are each optionally substituted with 1 to 4 groups independently selected from halogen and C 1-6 alkoxy; R 3 is H or C 1-6 alkyl, said C 1-6 alkyl being optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, C 1-4 alkoxy, -C(O)C 1-6 alkyl, and -C(O)N(R 4 ) 2 ; each R 4 is independently H or C 1-6 alkyl, or both R 4 , together with the nitrogen to which they are attached, form a 4- to 7-membered monocyclic heterocyclyl; Z is -C(O)R13, ​​-C(O)NR6R7, -S(O)2R6, a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; wherein said 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl are each independently optionally substituted with 1-2 R 8 groups, each independently optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; R 6 is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl, said C 1-4 alkoxy and C 1-5 alkyl each independently being substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, and -NR 12 R 12 ; R 13 is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; R 7 is H or C 1-6 alkyl, wherein said C 1-6 alkyl is optionally substituted with 1 to 4 groups independently selected from -OH, halogen, -CN and C 1-6 alkoxy; each R 8 is independently -C(O)R 9 , C 1-6 alkyl, 4- to 7-membered monocyclic heterocyclyl, or 6- to 10-membered bridged bicyclic heterocyclyl; C 1-6 alkyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1-4 alkoxy, and R 8a ; the 4- to 7-membered monocyclic heterocyclyl and the 6- to 10-membered bridged bicyclic heterocyclyl are each independently optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; R 8a is 4- to 7-membered monocyclic heterocyclyl; R 9 is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; each R 11 is independently H, C 1-6 alkyl, or C 3-7 monocyclic cycloalkyl, or 4- to 7-membered monocyclic heterocyclyl; each R 12 is independently H or C 1-4 alkyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; wherein the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 8- to 10-membered bridged bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heteroaryl each independently have 1 to 4 ring heteroatoms independently selected from N, O, and S, or a pharma- ceutically acceptable salt thereof.

4. R １ but, 【Chemical 276】 and Each of them is a halogen, C １～３ Alkyl and C １～３ Optionally substituted with 1 to 3 groups independently selected from alkoxy, wherein １～３ The alkyl is optionally substituted with 1 to 3 halogen groups; or R 1 is 【Chemical 277】 and optionally substituted with 1 to 3 groups independently selected from halogen, C 1-3 alkyl and C 1-3 alkoxy, wherein said C 1-3 alkyl is optionally substituted with 1 to 3 halogen groups; or R 1 is 【Chemical 278】 is; or R 1 is 【Chemical 279】 is; or R 1 is 【Chemistry 280】 is; or R 1 is 【Chemistry 281】 and each of which is optionally substituted with 1 to 3 groups independently selected from halogen, -CN, C1-3 alkyl and C1-3 alkoxy; or R 1 is 【Chemical 282】 2. The compound of claim 1, wherein:

5. R ２ But, C １～６ is alkyl; or R 2 is isopropyl or cyclopropyl; or R 2 is isopropyl; or R 3 is H or C 1-6 alkyl; or R 3 is C 1-4 alkyl optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN and C 1-3 alkoxy; or R 3 is H or methyl; or R 3 is methyl; or R 3 is methyl substituted with 1 to 3 halogen groups; or 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R3 is H, methyl, -CHF2, -CH2OH, -CH2OCH3, or ethyl.

6. Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; wherein the 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R ８ groups, each independently being selected from the group consisting of -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, and C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl; Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; wherein said 4- to 7-membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl are each independently optionally substituted with 1-2 R 8 groups, each independently optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; said 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently have 1 or 2 ring heteroatoms which are N; or Z is a 5- to 6-membered monocyclic heterocyclyl; said 5-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 R 8 groups, and is optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; said 5-6 membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N; or Z is pyrrolidinyl or piperidinyl, each optionally substituted with 1 to 2 R 8 groups, optionally substituted with 1 to 2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z is piperidinyl, said piperidinyl optionally substituted with one R 8 group; or Z is azetidinyl, said azetidinyl optionally substituted with one R 8 group; or Z is azepanyl, said azepanyl being optionally substituted with one R 8 group; or Z is phenyl, naphthalenyl, or a 6-membered monocyclic heteroaryl, each optionally substituted with 1-2 R 8 groups, and optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein Z is phenyl, pyridinyl, or pyrimidinyl, each optionally substituted with one R8 group.

7. Z is an 8- to 10-membered fused bicyclic heterocyclyl or an 8- to 10-membered fused bicyclic heteroaryl, each optionally containing 1 to 2 R ８ groups, optionally substituted with -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy and C １～５ substituted with 1 to 2 groups independently selected from alkyl; Z, 【Chemistry 285】 and each of which is optionally substituted with 1 to 2 R 8 groups, and optionally substituted with 1 to 2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z is a 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 R 8 groups and optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z is a 7-8 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 R 8 groups and optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl, said 7-8 membered bridged bicyclic heterocyclyl having 1 or 2 ring heteroatoms which are N; or Z is a 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 R 8 groups and optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z is a 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 R 8 groups optionally substituted with 1-2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl, said 7-10 membered spirocyclic heterocyclyl having 1 or 2 ring heteroatoms independently selected from N and O; or Z, 【Chemistry 286】 and each of which is optionally substituted with 1 to 2 R 8 groups, and optionally substituted with 1 to 2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z, 【Chemistry 287】 and each of which is optionally substituted with 1 to 2 R 8 groups, and optionally substituted with 1 to 2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z, 【Chemistry 288】 each of which is optionally substituted with 1 to 2 R 8 groups, and optionally substituted with 1 to 2 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or Z, 【Chemical 289】 and each of which is optionally substituted with one R 8 group; or Z substituted with one R 8 group is 【Chemistry 290】 is; or Z substituted with one R 8 group is 【Chemical 291】 is; or Z substituted with one R 8 group is 【Chemical 292】 is; or Z substituted with one R 8 group is 【Chemical 293】 is; or Z substituted with one R 8 group is 【Chemical 294】 is; or Z substituted with one R 8 group is 【Chemistry 295】 is; or Z substituted with one R 8 group is 【Chemical 296】 is; or Z substituted with one R 8 group is 【change】 is; or Z substituted with one R 8 group is 【Chemical 298】 2. The compound of claim 1, wherein:

8. R ８ C １～６ alkyl, １～６ Alkyl is -OH, halogen, -CN, oxo, -NR １１ R １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)NR １１ R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), C １～４ optionally substituted with 1 to 3 groups independently selected from alkoxy, 4- to 7-membered monocyclic heterocyclyl, and 5- to 6-membered monocyclic heteroaryl; or R 8 is C 1-6 alkyl, said C 1-6 alkyl being substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O) 2 R 11a , -S(O) 2 N(R 11 )(R 11 ), C 1-4 alkoxy, 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl; or R 8 is C 1-6 alkyl, said C 1-6 alkyl being substituted with 1 to 2 groups independently selected from -OH, -CN, oxo, -NR 11 R 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)NR 11 R 11 , -S(O) 2 R 11a , -S(O) 2 N(R 11 )(R 11 ), 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl; or R 11a is C 1-3 alkyl; or R 11 is independently H, C 1-4 alkyl, C 3-5 monocyclic cycloalkyl, or 4-6 membered monocyclic heterocyclyl; or R 8 is C 1-6 alkyl, said C 1-6 alkyl being -OH, -CN, oxo, -NH 2 , -N(CH 3 ) 2 , -C(O)(azetidinyl), -C(O)OH, -C(O)OCH(CH 3 ) 3 , -C(O)NH 2 , -C(O)NH 2 , -C(O)NH(CH 3 ), -C(O)NH(CH 2 CH 3 ), -C(O)NH(CH(CH 3 ) 2 ), -C(O)NH(cyclopropyl), -C(O)NH(oxetanyl), -C(O)N(CH 3 ) 2 , -S(O) 2 CH 3 , -S(O) 2 NH 2 , -S(O) 2 NH(CH 3 ), -S(O) 2 N(CH 3 ) 2 , 4- to 5-membered monocyclic heterocyclyl, and 5-membered monocyclic heteroaryl; or R 8 is C 1-3 alkyl, said C 1-3 alkyl being -OH, -CN, oxo, pyrrolidinyl, 【Chemistry 308】 or is substituted with 1 to 3 groups independently selected from R 8 is C 1-6 alkyl, said C 1-6 alkyl being substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH 3 ) 2 , -C(O)NH 2 , -S(O) 2 CH 3 , and oxetanyl; or R 8 is C 1-6 alkyl, said C 1-6 alkyl being substituted with 1 to 3 groups independently selected from -OH, oxo, -N(CH 3 ) 2 , -C(O)NH 2 , -C(O)NHCH 3 , -S(O) 2 CH 3 , oxetanyl, and pyrrolidinyl; or R 8 is C 1-3 alkyl, said C 1-3 alkyl being substituted with one group independently selected from -C(O)NH 2 and -C(O)NHCH 3 ; or R 8 is methyl substituted with one -C(O)NH 2 group; or R 8 is independently -NR 10 R 10 or -S(O) 2 R 5a ; or R 10 is independently H or 4-6 membered monocyclic heterocyclyl; or R 10 is independently H or oxetanyl; or R 5a is 4-6 membered monocyclic heterocyclyl; or R 5a is piperazinyl; or 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R 8 is --C(O)R 9 .

9. R ９ C ３～５ is a monocyclic cycloalkyl; ３～５ Monocyclic cycloalkyl is -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl; or R 9 is cyclopropyl, said cyclopropyl being optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, C 1-3 alkoxy, C 1-3 alkyl, and 5-6 membered monocyclic heterocyclyl; or R 9 is cyclopropyl, said cyclopropyl being substituted with morpholinyl; or R 9 is a 4- to 7-membered monocyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or R 9 is a 4- to 7-membered monocyclic heterocyclyl; said 4- to 7-membered monocyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; said 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N; or R 9 is a 4-6 membered monocyclic heterocyclyl, said 4-6 membered monocyclic heterocyclyl is optionally substituted with 1-2 groups independently selected from -OH, halogen, -NH 2 , C 1-3 alkoxy, and C 1-3 alkyl, and said 4-6 membered monocyclic heterocyclyl has 1 ring heteroatom which is N; or R 9 is independently azetidinyl or pyrrolidinyl, each of which is optionally substituted with 1 to 2 groups independently selected from -OH, halogen, C 1-3 alkoxy, and C 1-3 alkyl; or R 9 is independently 【Chemistry 309】 each of which may be substituted with one methyl group; or R 9 is independently oxetanyl, pyrrolidinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, C 1-3 alkoxy, and C 1-3 alkyl; or R 9 is independently an 8-10 membered fused bicyclic heterocyclyl, said 8-10 membered fused bicyclic heterocyclyl optionally substituted with 1-3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; or R 9 is independently an 8- to 10-membered fused bicyclic heterocyclyl; said 8-10 membered fused bicyclic heterocyclyl is optionally substituted with 1 to 3 groups independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1-4 alkoxy, and C 1-5 alkyl; said 8-10 membered fused bicyclic heterocyclyl has 1-3 ring heteroatoms independently selected from N and O; or R 9 is independently 【Chemistry 310】 is; or R 9 is a 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1-2 groups independently selected from -OH, halogen, C 1-3 alkoxy and C 1-3 alkyl, said 6-10 membered bridged bicyclic heterocyclyl having 1 ring heteroatom which is N; or R 9 is 【Chemistry 311】 and each of which is optionally substituted with 1 to 3 groups independently selected from fluoro, methoxy and methyl; or R 9 is a 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 groups independently selected from -OH, halogen, C 1-3 alkoxy and C 1-3 alkyl; or R 9 is a 9-membered spirocyclic heterocyclyl having 1 to 2 ring heteroatoms independently selected from N and O; or R 9 is 【Chemistry 312】 2. The compound of claim 1, wherein: 【Request 10】 【Chemical 314】 【Chemistry 315】 2. The compound of claim 1, selected from the group consisting of:

11. A) 【Chemistry 316】 【Chemistry 317】 【Chemistry 318】 or a pharma- ceutically acceptable salt thereof, or B) 【Chemical 319】 【Chemistry 320】 or a pharma- ceutically acceptable salt thereof, or C) 【Chemistry 321】 【Chemistry 322】 or a pharma- ceutically acceptable salt thereof, or D) 【Chemistry 323】 【Chemical 324】 or a pharma- ceutically acceptable salt thereof; or E) 【Chemistry 325】 【Chemical 326】 or a pharma- ceutically acceptable salt thereof; or F) 【Chemical 327】 【Chemical 328】 【Chemical 329】 【Chemistry 330】 or a pharma- ceutically acceptable salt thereof; or G) 【Chemistry 331】 or a pharma- ceutically acceptable salt thereof; or H) 【Chemical 332】 or a pharma- ceutically acceptable salt thereof; or I) 【Chemical 333】 or a pharma- ceutically acceptable salt thereof; or J) 【Chemical 334】 or a pharma- ceutically acceptable salt thereof; or K) 【Chemical 335】 or a pharma- ceutically acceptable salt thereof; or L) 【Chemical 336】 or a pharma- ceutically acceptable salt thereof; or M) 【Chemical 337】 or a pharma- ceutically acceptable salt thereof; or N) 【Chemical 338】 or a pharma- ceutically acceptable salt thereof; or O) 【Chemical 339】 or a pharma- ceutically acceptable salt thereof; or P) 【Chemistry 340】 【Chemical 341】 【Chemical 342】 【Chemical 343】 【Chemical 344】 or a pharma- ceutically acceptable salt thereof 2. The compound of claim 1 selected from the group consisting of:

12. 【Chemical 351】 2. The compound of claim 1, which is:

13. 【Chemical 352】 2. The compound of claim 1, which is: 【Request 14】 【353】 2. The compound of claim 1, which is:

15. 【Chemical 354】 2. The compound of claim 1, which is:

16. 【Chemical 355】 2. The compound of claim 1, which is:

17. 10. A pharmaceutical composition comprising a compound of claim 1, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient or carrier; and optionally further comprising one or more additional therapeutic agents, or pharma- ceutically acceptable salts thereof; The one or more additional therapeutic agents include an antimalarial agent; e.g., A pharmaceutical composition wherein the antimalarial agent is selected from chloroquine and hydroxychloroquine, or a pharma- ceutically acceptable salt thereof.

18. A pharmaceutical composition for the treatment of an inflammatory condition, comprising a compound according to claim 1 or a pharma- ceutical composition according to claim 17; and optionally or optionally, the inflammatory condition is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed connective tissue disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome-driven anemia of inflammation, IgA nephropathy, type I diabetes, nonalcoholic steatohepatitis, and Sjogren's syndrome; the inflammatory condition is systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis; optionally and optionally further comprising a therapeutically effective amount of one or more additional therapeutic agents or pharma- ceutically acceptable salts thereof; The one or more additional therapeutic agents are selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, celalizumab, daxudilimab, TAK-079, felzalutamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, ranalumab, LY-336 1237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacuzumab, bovalilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064, GNKS-356, AVO-101, rozibafusp α alfa), VRN-02, anexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256 (afimetoran), NKTR-35, atacicept, telitacicept, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, buldifurocept, LA-1, cenerimod, prednisone, corticotropin, deuclavacitinib, CPL-4091 16, CS-12192, tofacitinib citrate, ISB-830, DV-1079, duremic acid, iverdomid, TAM-01, BML-258, brepositinib, SDC-1801, SDC-1802, ICP-330, NTR-441, darazatide, GSK-2646264, SKI-O-703, ranlaprenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 biosimilar, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, ersbrutinib, olebrutinib, DWP-213388, INV-103, R-salbutamol sulfate, anchorins, NIK-SMI1, X-6, INV-17, OshadiD, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, azumometasone, betamethasone, folligerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edoratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712 , TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, cyclofosamide, rituximab, nonsteroidal anti-inflammatory drugs, belimumab, voclosporin, and AMG-592, or a pharma- ceutically acceptable salt of any of the foregoing, or any combination thereof; or optionally The pharmaceutical composition, wherein the subject is a human.

Images